BRIEF-Lysogene selects Brammer Bio to produce GM1 gangliosidosis gene therapy product – Reuters
|
BRIEF-Lysogene selects Brammer Bio to produce GM1 gangliosidosis gene therapy product
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … |
|
Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product
Business Wire (press release) Lysogene (Paris:LYS) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing agreement with … |
|
Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product
Business Wire (press release) Lysogene (Paris:LYS) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing agreement with … |
|
Cancer care: The limits of immunotherapy
Florida Trend Shortly after Donal O’Shea became president of New College of Florida in 2012, he met Teri Hansen, then head of the Gulf Coast Community Foundation, a philanthropic organization in Sarasota County. Hansen encouraged O’Shea to work closely with other … |
WDBJ7 |
VMI Cadet gives stem cells to save life
WDBJ7 Because at lacrosse camp his freshman year, he signed up with the HEADstrong foundation as a stem cell donor. And then: “I was in math class, and I thought something was wrong back home or something, because usually I don’t get phone call during class … |
|
California’s stem cell agency confronts uncertain future
Capitol Weekly Randal Mills, the 45-year-old CEO of California’s $3 billion stem cell research program, is a man who loves his milestones. A private pilot, he charts his course in the air from one specific point to the next. Three years ago, Mills brought that same … |
|
Stem cell agency’s response to questions about its performance
Capitol Weekly Ed’s Note: Here is the full text of the response from the California stem cell agency to a query about the five most important things that it thinks Californians should know about the $3 billion effort. The information was provided by Kevin McCormack … |